Aldeyra Therapeutics, Inc. (ALDX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ALDX
- Company Aldeyra Therapeutics, Inc.
- Price $1.24
- Changes Percentage -70.69
- Change -2.99
- Day Low $1.07
- Day High $1.51
- Year High $7.2
- Year Low $1.14
- Market Cap $301,515,738
- Price Avg 50 EMA (D) $5.02
- Price Avg 200 EMA (D) $4.83
- Exchange NASDAQ
- Volume 1,604,064
- Average Volume 1,078,393
- Open $1.12
- Previous Close $4.23
- EPS -0.56
- PE -8.95
- Earnings Announcement 2026-05-13 04:00:00
- Shares Outstanding $60,182,782
Company brief: ALDEYRA THERAPEUTICS, INC. (ALDX )
- Healthcare
- Biotechnology
- Dr. Todd C. Brady M.D., Ph.D.
- https://www.aldeyra.com
- US
- N/A
- 05-02-2014
- US01438T1060
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Corporation News
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
newsfilecorp.com -- San Diego, California--(Newsfile Corp. - March 17, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focus...
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
globenewswire.com -- Block & Leviton is investigating Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) for potential securities law violations. ALDX investors should contact the firm....
US FDA declines to approve Aldeyra's drug for eye disorder
reuters.com -- The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said....
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
businesswire.com -- LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...